More recently, Roboz et al. demonstrated that ivosidenib induced deep and durable remissions in treatment-naïve IDH1-mutant AML, with a CR/CRh rate of 42.4%, a mutation clearance in 64%, and in some cases (5/33) a durable remission beyond 2 years [24]. Here, IDH1 is linked to acute myeloid leukemia.